Drozitumab

Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.

Drozitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetDR5
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6334H9792N1700O2000S42
Molar mass143104.43 g·mol−1
 NY (what is this?)  (verify)

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.[2]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.